SCHEMBL187774

SCHEMBL187774

Cc1cc2cc[nH]c2cc1F

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.69
AHR P35869 7/20 0.50
CSNK2A1 P68400 1/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP2A6 P11509 3/20 0.41
NR4A2 P43354 2/20 0.41
CMA1 P23946 1/20 0.41
F7 P08709 1/20 0.41
LTA4H P09960 1/20 0.41
F3 P13726 1/20 0.41
TYR P14679 1/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
RAD51 Q06609 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
IMPDH2 P12268 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30370306 1.00 GPR84 (0.69) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL579164 0.92 GPR84 (0.69) GPR84AHRCSNK2A1MEN1POLB
Tert-Butyl Formate SCHEMBL27584210 0.83 GPR84 (0.49) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL188052 0.82 GPR84 (1.00) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL827047 0.82 GPR84 (0.54) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL8246776 0.79 GPR84 (0.52) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL10322228 0.79 GPR84 (0.62) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL916811 0.75 GPR84 (0.47) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL1609911 0.75 GPR84 (0.76) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL1401662 0.75 GPR84 (0.69) GPR84AHRCSNK2A1CYP2A6NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378243-B2 Quinoline compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2025-08-05 US disclosed
US-20250230127-A1 MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS JANSSEN PHARMACEUTICALS INC (US) 2025-07-17 US disclosed
US-12172959-B2 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors Janssen Pharmaceuticals, Inc. (US) 2024-12-24 US disclosed
EP-3436004-B1 SUBSTITUTED INDOLE COMPOUND DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS JANSSEN PHARMACEUTICALS INC (US) 2024-12-11 EP disclosed
US-20240368152-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION 2024-11-07 US disclosed
CN-118525017-A Quinoline compounds as KRAS inhibitors 因赛特公司 2024-08-20 CN disclosed
CN-113045476-B Monosubstituted or disubstituted indole derivatives as dengue virus replication inhibitors 杨森制药公司 2024-07-16 CN disclosed
US-20240182414-A1 MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS Janssen Pharmaceuticals, Inc. (US) 2024-06-06 US disclosed
US-11939328-B2 Quinoline compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2024-03-26 US disclosed
CN-111303000-B Monosubstituted or disubstituted indole derivatives as dengue virus replication inhibitors 杨森制药公司 2023-11-28 CN disclosed
US-8003647-B2 (Aza)indole derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-08-23 US disclosed
CN-101679251-A (Aza)indole derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL 2010-03-24 CN disclosed
US-20100056521-A1 (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-03-04 US disclosed
US-20100056521-A1 (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-03-04 US disclosed
US-20100056521-A1 (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-03-04 US disclosed
EP-2133332-A1 (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Kissei Pharmaceutical Co., Ltd. (JP) 2009-12-16 EP disclosed
US-5834494-A SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME SMITHKLINE BEECHAM P.L.C. (GB) 1998-11-10 US disclosed
EP-0707581-B1 INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1997-02-26 EP disclosed
EP-0707581-A1 INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1996-04-24 EP disclosed
WO-1995001976-A1 INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1995-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378243-B2 Quinoline compounds as inhibitors of KRAS KRAS, NRAS, HRAS GPR84 3564/4885AHR 3011/4885CSNK2A1 613/4885
US-20240368152-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS GPR84 3564/4885AHR 3011/4885CSNK2A1 613/4885
US-20100056521-A1 (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, DAO, TDO2 GPR84 2193/4885AHR 449/4885CSNK2A1 2543/4885
US-20250230127-A1 MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS IDO1, IDO2, IRF3 GPR84 2584/4885AHR 429/4885CSNK2A1 4254/4885
US-20240182414-A1 MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS IDO1, IDO2, IRF3 GPR84 2516/4885AHR 459/4885CSNK2A1 4198/4885
US-12172959-B2 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors IDO1, IDO2, IRF3 GPR84 2516/4885AHR 459/4885CSNK2A1 4198/4885
US-11939328-B2 Quinoline compounds as inhibitors of KRAS KRAS, NRAS, HRAS GPR84 3564/4885AHR 3011/4885CSNK2A1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.